LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

Drinks all round then Cynic?

... tomato-based of course...

even for marni!

looks like another cycle of strong rises coming around.....

A couple of hefty buys just gone through. Somebody likes Sirco!

And very confident with it!!!!!!

Indeed!

You are all going to get your fingers burnt..if you are not careful on this one....weird stock...can't make sense of how this is valued...a major order for whatever it does has to come to justify the sp as it now stands ..otherwise...the abyss again....I would jump in again myself but it's the sort of stock as in dreams or nightmares...

rf are you a shorter then?

I have never shorted in my life...would love to try it out one day : but I have to be sure..the trouble with shorting is that you can nearly always pick out a riser and go for that, shorting is very tricky...but I wouldn't risk it on this one...at the moment.

More of a gradual rise this time. More stability. When the ec wording confirmation comes through. Which imo is granteed too be in one form or another, the deals will follow and that will justify the valuation and way more. aimvho, dyor, gl, fib.

RF ...... i would agree with you 120% were it not for the consistent strength linked to consistently high volumes - 20m today; norm 9.5m and yesterday may have been heavier still, but i can't remember

And the bulls will turn into bears just like that on this one....75 million and 5000 earnings : I mean : turning tomatoes into gold might justify this valuation....I just can't bring myself around to jumping back in here...I thought it was a miracle last time I made a small buck...

Are these people going to produce the aspirin replacement ?....it's going to take ages before the Americans allow this into their airspace....a big boy participation is a must be for this now...Glaxo, Unilever and sorts spring to mind...

i cannot disagree one iota with your logic, but just maybe there is more to this headlong rush for the stars than mere lemming hype - e.g. an announcement that a licencing deal has indeed been struck with Coca Cola or similar

Well...if that is the case then possibly zoom....but I prefer my oilies...too risky for me in case of a no show from the soft drink people...

and oilies aren't?????????

cynic you may be right but it has to be a massive deal to justify a market cap of around 100m.

quite so or t/o, so i am contemplating my navel accordingly

required field, to quote "a major order for whatever it does"

do you know anything about this company, its products, research, agreements or current situation? Agreed it has a high valuation and has low revenue but it has had an agreement with unilever and coca cola for the last two years plus. It is the only company that has an approved EC scientific claim for food under article 13.5.
It is about to announce trial results from comparisons with aspirin for health benefits.
It has a major shareholder in DSM which is the worlds top 3 ingredients producer/developer. It has directors with connections to a major pharmaceutical company.

All of this is lining up to produce sizeable revenues - agreed we are not aware of details as yet but the markets for the product is huge, in the multi billion range for both food and also alternative to daily aspirin as preventitive therapy.

The current key announcement is the final EC wording approval. Whether this swings around some more, the sp has made and will keep its major change from its previous ranges.